Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: A NICE single technology appraisal

PharmacoEconomics

Volumn 30, Issue 11, 2012, Pages 991-1004

  Burch, Jane ^a   Griffin, Susan ^a   McKenna, Claire ^a   Walker, Simon ^a   Paton, James ^b   Wright, Kath ^a   Woolacott, Nerys ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; OMALIZUMAB;

ACADEMIC ACHIEVEMENT; ADD ON THERAPY; ALLERGIC ASTHMA; BUDGET; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MEGADOSE; EMOTIONAL STRESS; FOLLOW UP; FORCED EXPIRATORY FLOW; HOSPITALIZATION; HUMAN; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEVERE PERSISTENT ASTHMA; SKIN TEST; SLEEP DEPRIVATION; SOCIAL LIFE; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ADULT; AGE FACTORS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; COST-BENEFIT ANALYSIS; ENGLAND; HUMANS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TECHNOLOGY ASSESSMENT, BIOMEDICAL; WALES;

EID: 84867292926     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11597160-000000000-00000     Document Type: Review

References (42)

1. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008
2. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal (STA) process. London: NICE, 2006
3. Walker S, Burch J, McKenna C, et al. Omalizumab for the treatment of severe persistent asthma in children aged 6 to 11 years. London: NICE, 2010
4. Sculpher M. Single technology appraisal at the UK National Institute for Health and Clinical Excellence: a source of evidence and analysis for decision making internationally. Pharmacoeconomics 2010; 28 (5): 347-9
5. Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics 2010; 28 (5): 351-62
6. Bagust A, Greenhalgh J, Boland A, et al. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics 2010; 28 (6): 439-48
7. Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics 2011; 29 (2): 133-40
8. Scotland G, Waugh N, Royle P, et al. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. Pharmacoeconomics 2011; 29 (11): 951-61
9. Dickson R, Bagust A, Boland A, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. Pharmacoeconomics 2011; 29 (12): 1051-62
10. McKenna C, Maund E, Sarowar M, et al. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics 2012; 30 (1): 35-46
11. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a NICE single technology appraisal. Pharmacoeconomics 2012; 30 (2): 137-46
12. Yang H, Craig D, Epstein D, et al. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics 2012; 30 (4): 257-70
13. Boyers D, Jia X, Jenkinson D, et al. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics 2012; 30 (6): 483-95
14. Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. Pharmacoeconomics. In press
15. Kilonzo M, Hislop J, Elders A. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal. Pharmacoeconomics. In press
16. Craig D, Rice S, Paton F, et al. Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalization: a NICE single technology appraisal. Pharmacoeconomics. In press
17. Simpson EL, Fitzgerald P, Evans P, et al. Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal. Pharmacoeconomics. In press
18. Armstrong N, Manuela J, van Asselt T, et al. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. Pharmacoeconomics. In press
19. National Institute for Health and Clinical Excellence. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years [NICE technology appraisal guidance no. TA201]. London: NICE, 2010 [online]. Available from URL: http://publications.nice.org.uk/omalizumab-for-the- treatment-of-severe-persistent-allergicasthma-in-children-aged-6-to-11-years- ta201 [Accessed 2012 Aug 13]
20. Asthma UK. Facts for journalists [online]. Available from URL: http://www.asthma.org.uk/news-media/media-resources/for-journalists-key.html [Accessed 2010 Sept 16]
21. Novartis Pharmaceuticals UK Ltd. Single technology appraisal (STA) manufacturer submission of evidence: Xolair® (omalizumab) for severe persistent allergic asthma in children aged 6-<12 years. London: NICE, 2009
22. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124 (6): 1210-6
23. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108 (2): E36
24. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60 (3): 309-16
25. Watson L, Turk F, James P, et al. Factors associated with mortality after an asthma admission: a national United Kingdom database analysis. Respir Med 2007; 101: 1659-64
26. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Resp J 2007; 16 (1): 22-7
27. Scottish Intercollegiate Guidelines Network, British Thoracic Society. British guideline on the management of asthma: a national clinical guideline. Edinburgh: SIGN, 2009
28. National Institute for Health and Clinical Excellence. Final appraisal determination: omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years. London: NICE, 2010 Aug [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/12266/50295/50295.pdf [Accessed 2010 Sep 15]
29. National Institute for Health and Clinical Excellence. Asthma (in children): omalizumab. Appraisal consultation document (ACD). London: NICE, 2010 [online]. Available from URL: http://guidance.nice.org.uk/TA/Wave22/9/ Consultation/DraftNICEGuidance [Accessed 2012 Aug 13]
30. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004
31. Claxton K, Walker S, Palmer S, et al. Appropriate perspectives for health care decisions. York: Centre for Health Economics, 2010
32. Neumann PJ, Drummond M, Jonsson B, et al. Are key principles for improved health technology assessment supported and used by health technology assessment organizations? Int J Technol Assess Health Care 2010; 26 (1): 71-8
33. National Institute for Health and Clinical Excellence. Omalizumab for severe persistent allergic asthma [NICE technology appraisal guidance no. TA133]. London: NICE, 2007
34. Scottish Medicines Consortium. Omalizumab 150 mg powder and solvent for injection (Xolair®) [online]. Available from URL: http://www. scottishmedicines.org.uk/SMC-Advice/Advice/Omalizumab-Xolair-/ omalizumab-150mg-powder-and-solvent-for-injection-Xolair-1 [Accessed 2010 Sep 15]
35. NHS. NHS Constitution [online]. Available from URL: http://www.nhs.uk/ choiceintheNHS/Rightsandpledges/NHSConstitution/Pages/Overview.aspx [Accessed 2010 Sep 30]
36. Royal College of Paediatrics and Child Health. NICE omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years: appraisal consultation document (ACD) - Royal College of Paediatrics and Child Health response [online]. Available from URL: http://www.nice.org.uk/nicemedia/ live/12266/50304/50304.pdf [Accessed 2010 Sep 15]
37. Primary Care Respiratory Society UK. Appraisal consultation document: omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years-comments from Primary Care Respiratory Society UK. 2010 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/12266/50302/ 50302.pdf [Accessed 2010 Sep 15]
38. Andrews S. Named patient medicines: a pharmacist's perspective. Oncology News 2006; 1 (3): 10-11 [online]. Available from URL: http://www.oncologynews. biz/pdf/oct-nov/ON-ON06-08.pdf [Accessed 2010 Sep 28]
39. Herefordshire NHS Primary Care Trust. Policy on individual funding requests. 2009 Jun [online]. Available from URL: http://www.herefordshire.nhs. uk/docs/publications/hpct-ifr-policy-june-2009-final.pdf [Accessed 2010 Sep 28]
40. National Institute for Health and Clinical Excellence. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11: response to consultee, commentator and public comments on the appraisal consultation document (ACD). London: NICE, 2010
41. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 2000; 320: 79-82
42. National Institute for Health and Clinical Excellence. Consideration of consultation responses on review proposal: review of TA133 - omalizumab for severe persistent allergic asthma. London: NICE, 2010 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/11894/51714/51714.pdf [Accessed 2012 Aug 13]